Glaucoma News

BYD God’s Eye Self-Driving Faces Major Issues

BYD God’s Eye Self-Driving Faces Major Issues

BYD’s God’s Eye Self-Driving System Faces Major Technical Setbacks The race for autonomous driving supremacy is a marathon, not a sprint, and even the frontrunners can stumble. BYD, the Chinese electric vehicle giant that recently dethroned Tesla in global EV sales, is facing a significant hurdle in its quest for technological dominance. Its highly anticipated […]

BYD God’s Eye Self-Driving Faces Major Issues Read More »

Ocugen Gene Therapy Hits Targets, Disappoints Investors

Ocugen Falls as Eye Gene Therapy Lags in Phase II

Ocugen Stock Drops After Eye Disease Gene Therapy Trial Disappoints The world of biotechnology is a high-stakes arena, where a single clinical trial result can send a company’s valuation soaring or plummeting. This volatile reality hit home for Ocugen, Inc. (NASDAQ: OCGN) this week, as the company’s shares experienced a sharp decline following the release

Ocugen Falls as Eye Gene Therapy Lags in Phase II Read More »

Scroll to Top